GAMMA Investing LLC Purchases Shares of 1,877 Danaher Co. (NYSE:DHR)

GAMMA Investing LLC bought a new stake in shares of Danaher Co. (NYSE:DHR) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,877 shares of the conglomerate’s stock, valued at approximately $450,000.

Other large investors also recently added to or reduced their stakes in the company. Banco Santander S.A. bought a new stake in Danaher in the third quarter worth $683,000. First Citizens Bank & Trust Co. raised its position in Danaher by 0.6% in the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after purchasing an additional 149 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in Danaher by 48.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after purchasing an additional 96,395 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Danaher by 4.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock worth $764,000 after acquiring an additional 142 shares in the last quarter. Finally, Keybank National Association OH grew its holdings in shares of Danaher by 0.5% during the third quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock worth $137,238,000 after purchasing an additional 2,567 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on DHR. Citigroup lifted their price target on shares of Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Barclays raised their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday. TD Cowen upped their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Bank of America increased their price objective on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $269.38.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Teri List sold 3,289 shares of Danaher stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock valued at $8,265,802 in the last quarter. 10.90% of the stock is currently owned by company insiders.

Danaher Trading Down 1.1 %

NYSE DHR traded down $2.72 during trading hours on Wednesday, reaching $250.39. The company’s stock had a trading volume of 1,314,251 shares, compared to its average volume of 2,758,515. The stock has a market cap of $185.42 billion, a P/E ratio of 39.15, a P/E/G ratio of 3.96 and a beta of 0.83. The firm has a fifty day simple moving average of $248.95 and a 200-day simple moving average of $230.64. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.36 EPS. Equities analysts forecast that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. Danaher’s dividend payout ratio (DPR) is 16.90%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.